Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

ClinicalTrials.gov ID: NCT00715910

Public ClinicalTrials.gov record NCT00715910. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine Versus Menactra® in Healthy Adolescents/Adults Aged 10-25 Years and Booster Response to MenACWY-TT Vaccine Administered at 5 Years Post-primary Vaccination

Study identification

NCT ID
NCT00715910
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
818 participants

Conditions and interventions

Interventions

  • Nimenrix Biological
  • Blood sampling Procedure

Biological · Procedure

Eligibility (public fields only)

Age range
15 Years to 30 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2008
Primary completion
Mar 31, 2013
Completion
Sep 30, 2013
Last update posted
Nov 26, 2014

2008 – 2013

United States locations

U.S. sites
10
U.S. states
2
U.S. cities
9
Facility City State ZIP Site status
GSK Investigational Site Daly City California 94015
GSK Investigational Site Fairfield California 94533
GSK Investigational Site Redwood City California 94063
GSK Investigational Site Sacramento California 95815
GSK Investigational Site Vallejo California 94589
GSK Investigational Site Walnut Creek California 94596
GSK Investigational Site Honolulu Hawaii 96814
GSK Investigational Site Honolulu Hawaii 96819
GSK Investigational Site Waianae Hawaii 96792
GSK Investigational Site Waipio Hawaii 96797

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00715910, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 26, 2014 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00715910 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →